ASCO24 Updates: Survival Outcomes: Neoadjuvant vs. Adjuvant Therapy in NSCLC
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.
This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.
In this video, Ghanshyam Ghelani, Hematology/Oncology Fellow at the State University of New York Upstate Medical University, shares insights about their poster on “Comparative survival after neoadjuvant vs adjuvant systemic therapy in resectable stage II and stage III non-small cell lung cancer: A retrospective study using the National Cancer Database.”
Dr. Ghelani also had a publication only at this year’s meeting titled “Peripheral blood biomarkers in immune checkpoint inhibition therapy in metastatic melanoma.”
More videos and content from ASCO 2024 on OncoDaily.